Side-by-side comparison of AI visibility scores, market position, and capabilities
Finch Therapeutics develops microbiome-based medicines targeting the gut-brain and gut-immune axis with programs in autism spectrum disorder and C. difficile.
Finch Therapeutics is a clinical-stage biotechnology company founded in 2015 that develops microbiome medicines targeting the relationship between the gut microbiome and systemic diseases. The company is focused on two primary therapeutic areas: gastrointestinal infections including C. difficile and conditions involving the gut-brain axis including autism spectrum disorder where gut microbiome alterations have been associated with symptom severity. Finch's lead microbiome program CP101 targets recurrent C. difficile infection, competing in the same emerging microbiome therapeutics space as Seres Therapeutics. The company also conducts research on the COMET platform for autism spectrum disorder, exploring whether microbiome restoration can improve behavioral symptoms through the gut-brain connection. Finch has raised over $165M and has conducted multiple clinical trials of its microbiome medicines. The company's autism program represents a particularly innovative and scientifically ambitious program given the emerging evidence that gut microbiome composition influences neurological development and behavior. Finch's work contributes to the broader scientific validation of microbiome medicine as a legitimate therapeutic class beyond C. difficile.
Adept AI raised $415M to pioneer computer-use AI agents; its core research and agent team moved to Amazon in 2024 in a landmark talent acquisition while the company continues developing ACT-1 for enterprise automation.
Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and executing multi-step workflows in any application. Its ACT-1 model demonstrated the ability to control web browsers and desktop applications through natural language instructions, pioneering the computer-use agent paradigm that Anthropic later commercialized with Claude's computer use feature.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.